Objective and Subjective Outcomes of a Trifocal IOL in Eyes With Different AL
Completed
- Conditions
- CataractMyopiaLenses, IntraocularPresbyopiaSatisfaction
- Interventions
- Other: AT LISA tri 839MP (Carl Zeiss Meditec AG)
- First Posted Date
- 2022-06-24
- Last Posted Date
- 2022-06-24
- Lead Sponsor
- Peking University Third Hospital
- Target Recruit Count
- 61
- Registration Number
- NCT05431868
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, Beijing, China
Effect of Dietary Fiber Intervention on Patients With Polycystic Ovary Syndrome
Not Applicable
Recruiting
- Conditions
- Polycystic Ovary Syndrome
- Interventions
- Dietary Supplement: Dietary intervention
- First Posted Date
- 2022-06-24
- Last Posted Date
- 2023-05-19
- Lead Sponsor
- Peking University Third Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT05431816
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, Beijing, China
Absorbable Interface Screw Clinical Trial
Not Applicable
- Conditions
- Anterior Cruciate Ligament Rupture
- Interventions
- Device: Absorbable interface screws manufactured by Natong BiotechnologyDevice: Absorbable interface screws manufactured by INION.
- First Posted Date
- 2022-06-24
- Last Posted Date
- 2022-06-24
- Lead Sponsor
- Peking University Third Hospital
- Target Recruit Count
- 86
- Registration Number
- NCT05431790
Ibrutinib Combined With R-CHOP/R-DHAP in Newly Diagnosed Mantle Cell Lymphoma Patients Who Aged ≤65 Years
- Conditions
- Mantle Cell Lymphoma
- First Posted Date
- 2022-06-23
- Last Posted Date
- 2022-06-23
- Lead Sponsor
- Peking University Third Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT05429918
- Locations
- 🇨🇳
Hongmei Third Jing, Beijing, Beijing, China
Risk Factors and Biomarkers for Post-tuberculosis Lung Damage
Recruiting
- Conditions
- Pulmonary TB
- Interventions
- Other: no intervention
- First Posted Date
- 2022-06-22
- Last Posted Date
- 2022-06-22
- Lead Sponsor
- Peking University Third Hospital
- Target Recruit Count
- 400
- Registration Number
- NCT05426720
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, China
🇨🇳Beijing Geriatric Hospital, Beijing, China
3D-PCT Combined With CT-guided Radioactive I-125 Seed Implantation in the Treatment of Head and Neck Tumors
Recruiting
- Conditions
- Malignant Tumor of Head and/or Neck
- Interventions
- Radiation: Radioactive Iodine-125 Seeds Implantation
- First Posted Date
- 2022-06-16
- Last Posted Date
- 2022-07-20
- Lead Sponsor
- Peking University Third Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT05421507
- Locations
- 🇨🇳
Department of Radiation Oncology of Peking university third hospital, Beijing, China
Accuracy of Coplanar Template Assistance for Pelvic and Groin Areas Biopsy
- Conditions
- Pelvic and Groin Areas Biopsy
- First Posted Date
- 2022-06-15
- Last Posted Date
- 2022-07-20
- Lead Sponsor
- Peking University Third Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT05419141
- Locations
- 🇨🇳
Bin Qiu, M.D., Beijing, China
🇨🇳Peking University Third Hospital, Beijing, Beijing, China
The ctDNA for Evaluating Whether to Use Adjuvant Therapy After SBRT in Patients With Early Lung Cancer
Not Applicable
Not yet recruiting
- Conditions
- Stereotactic Body Radiation Therapy
- Interventions
- Drug: drug adjuvant therapy
- First Posted Date
- 2022-06-09
- Last Posted Date
- 2022-06-09
- Lead Sponsor
- Peking University Third Hospital
- Target Recruit Count
- 180
- Registration Number
- NCT05411809
- Locations
- 🇨🇳
Department of Radiation Oncology Cancer Center, Peking University Third Hospital 49# North Garden Rd.,Haidian Dist., Beijing, Beijing, China
Accuracy of Coplanar Template Assistance for Abdominal Tumor Puncture
- Conditions
- Abdominal Tumor
- First Posted Date
- 2022-06-07
- Last Posted Date
- 2022-07-19
- Lead Sponsor
- Peking University Third Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT05408819
- Locations
- 🇨🇳
Department of Radiation Oncology of Peking university third hospital, Beijing, China
Ibrutinib Combined With Bendamustine and Rituximab in Newly Diagnosed Mantle Cell Lymphoma Patients Who Aged > 65 Years
- Conditions
- Mantle Cell Lymphoma (MCL)
- First Posted Date
- 2022-06-06
- Last Posted Date
- 2022-06-06
- Lead Sponsor
- Peking University Third Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT05406154
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, Beijing, China
© Copyright 2025. All Rights Reserved by MedPath